801 ORAL High Throughput Molecular Analyses to Select Patients for Targeted Agents
- 作者M. Arnedos; J. De La Cruz; B. Job; V. Scott; P. Dessen; D. Gentien; S. Roman-Roman; S. Delaloge; V. Lazar; F. Andre
- 卷第47卷
- 印刷ISSN0959-8049
- 文件大小42.94KB
- 发表时间2011
- DOI10.1016/s0959-8049(11)70638-4
The Oral Fluorinated PyrimidinesJ.S. de Bono; C.J. Twelves · 2001
20 Improving outcome from advanced prostate cancer through rational drug developmentJ.S. de Bono · 2011
Molecular alterations and emerging targets in castration resistant prostate cancerLorente, D.; De Bono, J.S. · European Journal of Cancer · 2014
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centreB. Pamenter; J.S. De Bono; I.L. Brown; M. Nandini; S.B. Kaye; J.M. Russell; A.J. Yates; D. Kirk · 2003
118 POSTER Comparative pharmacokinetic study of abiraterone acetate in a capsule and tablet formulationF.I. Raynaud; V. Martins; T. Yap; C. Carden; R.L. Jones; S.B. Riggs; F.F. Kabbinavar; D. McIntosh; G. Lee; J.S. De Bono · 2008
764PDA RANDOMISED PHASE II TRIAL OF DEXAMETHASONE VERSUS PREDNISOLONE IN CASTRATION RESISTANT PROSTATE CANCERParker, C.; Venkitaraman, R.; Lorente, D.; Murthy, V.; Thomas, K.; Ahiabor, R.; Dearnaley, D.; Huddart, R.; de Bono, J.S. · Annals of Oncology · 2014
Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unitSundar, R.; Custodio, A.; Lim, J.; Chenard-Poirier, M.; Collins, D.; Kaye, S.; Yap, T.A.; Banerji, U.; Lopez, J.; de Bono, J.S. · Annals of Oncology · 2016